StockVS

Labcorp Holdings Inc. (LH) स्टॉक विश्लेषण

स्वास्थ्य सेवा

Labcorp Holdings Inc.

$258.45

$-1.48 (-0.57%)

अंतिम अपडेट: 26 मई 2026

प्राइस हिस्ट्री

हाल की खबरें

तृतीय-पक्ष स्रोतों द्वारा प्रदान की गई समाचार। वित्तीय सलाह नहीं है।

विश्लेषण

कंपनी का अवलोकन

Labcorp Holdings Inc. operates as a premier provider of comprehensive laboratory services, delivering critical diagnostic and research solutions essential for modern healthcare ecosystems. The enterprise functions within the broader Healthcare sector, specifically specializing in the Diagnostics & Research industry, where it supports clinical decision-making through advanced testing capabilities. This organization employs a substantial workforce of 61,770 individuals and holds a significant market capitalization of $22.65 billion. Its annual revenue generation stands at $13.95 billion, positioning the firm as a dominant player with substantial operational scale. These valuation and revenue metrics indicate that the company commands a prominent position in the diagnostic testing landscape, reflecting deep market penetration and established trust among healthcare providers. The extensive employee base further underscores its capacity to manage complex logistics and deliver high-volume testing across diverse geographic regions.

वित्तीय स्वास्थ्य

The company reported a trailing twelve-month revenue of $13.95 billion, generating a net income of $876.50 million and an EBITDA of $2.19 billion. The substantial gap between the revenue figure and the net income highlights a cost structure where operating expenses, including labor and reagent costs, consume a significant portion of top-line growth before reaching the bottom line. Free cash flow stands at $966.63 million, providing the organization with robust financial flexibility to fund operations, invest in technology, or manage capital allocation without relying heavily on external financing. Gross margin is recorded at 28.8%, indicating the portion of revenue remaining after direct costs, while the operating margin of 10.6% reflects efficiency in managing overhead and administrative functions. The profit margin of 6.3% demonstrates the final percentage of revenue converted into actual profit available to shareholders. On the liquidity and solvency front, total cash holdings of $532.30 million are compared against total debt of $6.53 billion, resulting in a debt-to-equity ratio of 75.56, which suggests a leveraged balance sheet relative to equity. The current ratio of 1.42 indicates that the company possesses sufficient current assets to cover its short-term liabilities, ensuring adequate short-term liquidity. Return on Equity is calculated at 10.5%, while Return on Assets stands at 5.1%, revealing the effectiveness of management in generating returns relative to the capital invested and the total asset base utilized.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is 26.10, whereas the forward P/E is 14.17, implying that the market expects earnings growth that would justify a lower multiple in the future relative to current performance levels. The price-to-book ratio is 2.61, suggesting that the stock trades at a premium of 161% above its tangible book value, reflecting investor confidence in the company's intangible assets and future cash flow potential. Alternative valuation metrics include a price-to-sales ratio of 1.62 and an EV/EBITDA of 13.02, which provide a broader perspective on value by incorporating enterprise value and sales efficiency rather than just earnings per share. Regarding trading range, the 52-week high is $293.72 and the 52-week low is $209.38, meaning the current valuation sits between these historical extremes, though the specific current price is not listed in the provided data. The beta value of 0.98 indicates that the stock's price volatility closely mirrors that of the broader market, moving in tandem with overall market fluctuations rather than exhibiting excessive sensitivity to market swings.

Growth & Income

Revenue growth year-over-year is 5.6%, while earnings growth year-over-year reaches 15.7%, demonstrating that profitability is expanding at a pace significantly faster than top-line sales. This divergence implies that the company is improving its cost efficiency or leveraging pricing power to drive net income growth disproportionately to revenue expansion. As a dividend payer, the company offers a dividend yield of 1.1% with a payout ratio of 27.5%, indicating that the dividend is highly sustainable as it covers less than one-third of the earnings generated. The low payout ratio allows the firm to retain the majority of earnings for reinvestment in research, development, and operational expansion rather than distributing them entirely. The overall profile combines moderate revenue expansion with accelerated earnings growth and a conservative, sustainable dividend policy that balances income generation with capital reinvestment needs.

समकक्ष तुलना

Labcorp Holdings Inc. (LH) निदान और अनुसंधान उद्योग में कार्यरत है। बाजार पूंजीकरण के आधार पर इसके निकटतम समकक्षों से तुलना इस प्रकार है:

कंपनी टिकर मार्केट कैप P/E अनुपात
Labcorp Holdings Inc. LH $21.19B 22.9
Thermo Fisher Scientific Inc. TMO $166.55B 24.6
Danaher Corporation DHR $122.31B 33.4
IDEXX Laboratories, Inc. IDXX $43.95B 41.0

निदान और अनुसंधान उद्योग का औसत P/E अनुपात 32.5x है। Labcorp Holdings Inc. का P/E अनुपात 22.9 है।

यह विश्लेषण AI द्वारा केवल सूचनात्मक उद्देश्यों के लिए तैयार किया गया है और यह वित्तीय सलाह नहीं है। डेटा में देरी या अशुद्धि हो सकती है। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और किसी योग्य वित्तीय सलाहकार से परामर्श लें।

Labcorp Holdings Inc. के बारे में

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

कंपनी विवरण अंग्रेजी में दिखाया गया है।

वेबसाइट देखें →

मुख्य आंकड़े

मार्केट कैप
$21.19B
P/E अनुपात
22.89
52 सप्ताह उच्च
$293.72
52 सप्ताह निम्न
$241.81
औसत वॉल्यूम
615.45K
बीटा
0.88
डिविडेंड यील्ड
1.11%

डेटा yfinance के माध्यम से Yahoo Finance द्वारा प्रदान किया गया है। दैनिक अपडेट।

कंपनी जानकारी

एक्सचेंज
NYSE
देश
United States
कर्मचारी
71,000